| Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer H Borghaei, L Paz-Ares, L Horn, DR Spigel, M Steins, NE Ready, ... New England Journal of Medicine 373 (17), 1627-1639, 2015 | 9218 | 2015 |
| Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373 (9674), 1525-1531, 2009 | 1780 | 2009 |
| Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy … EB Garon, TE Ciuleanu, O Arrieta, K Prabhash, KN Syrigos, T Goksel, ... The Lancet 384 (9944), 665-673, 2014 | 1336 | 2014 |
| Nivolumab versus docetaxel in previously treated patients with advanced non–small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials … L Horn, DR Spigel, EE Vokes, E Holgado, N Ready, M Steins, ... Journal of clinical oncology 35 (35), 3924, 2017 | 818 | 2017 |
| Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases EE Vokes, N Ready, E Felip, L Horn, MA Burgio, SJ Antonia, OA Frontera, ... Annals of oncology 29 (4), 959-965, 2018 | 440 | 2018 |
| Five-year outcomes from the randomized, phase III trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non–small-cell lung cancer H Borghaei, S Gettinger, EE Vokes, LQM Chow, MA Burgio, ... Journal of Clinical Oncology 39 (7), 723, 2021 | 351 | 2021 |
| Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin … O Arrieta, RM Michel Ortega, G Villanueva-Rodríguez, MG Serna-Thomé, ... BMC cancer 10, 1-7, 2010 | 351 | 2010 |
| Association of depression and anxiety on quality of life, treatment adherence, and prognosis in patients with advanced non-small cell lung cancer Ó Arrieta, LP Angulo, C Núñez-Valencia, Y Dorantes-Gallareta, ... Annals of surgical oncology 20, 1941-1948, 2013 | 320 | 2013 |
| A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors M Candelaria, D Gallardo-Rincón, C Arce, L Cetina, JL Aguilar-Ponce, ... Annals of Oncology 18 (9), 1529-1538, 2007 | 287 | 2007 |
| Triple‐negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity F Lara‐Medina, V Pérez‐Sánchez, D Saavedra‐Pérez, M Blake‐Cerda, ... Cancer 117 (16), 3658-3669, 2011 | 283 | 2011 |
| Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non-small cell lung cancer: randomised … K Sánchez-Lara, JG Turcott, E Juárez-Hernández, C Nuñez-Valencia, ... Clinical nutrition 33 (6), 1017-1023, 2014 | 236 | 2014 |
| Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study N van Es, M Di Nisio, G Cesarman, A Kleinjan, HM Otten, I Mahé, IT Wilts, ... haematologica 102 (9), 1494, 2017 | 210 | 2017 |
| Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). ASCO Annual Meeting Proceedings J Clin Oncol 33, 2015 (suppl; abstr LBA109 …, 0 | 207* | |
| Updated frequency of EGFR and KRAS mutations in nonsmall-cell lung cancer in Latin America: the Latin-American Consortium for the Investigation of Lung Cancer (CLICaP) O Arrieta, AF Cardona, C Martín, L Más-López, L Corrales-Rodríguez, ... Journal of Thoracic Oncology 10 (5), 838-843, 2015 | 193 | 2015 |
| Association of nutrition parameters including bioelectrical impedance and systemic inflammatory response with quality of life and prognosis in patients with advanced non-small … K Sánchez-Lara, JG Turcott, E Juárez, P Guevara, C Núñez-Valencia, ... Nutrition and cancer 64 (4), 526-534, 2012 | 178 | 2012 |
| Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis O Arrieta, D Saavedra-Perez, R Kuri, A Aviles-Salas, L Martinez, ... BMC cancer 9 (1), 1-9, 2009 | 178 | 2009 |
| Angiotensin II, cell proliferation and angiogenesis regulator: biologic and therapeutic implications in cancer E Escobar, TS Rodriguez-Reyna, O Arrieta, J Sotelo Current vascular pharmacology 2 (4), 385-399, 2004 | 174 | 2004 |
| The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis O Arrieta, B Cacho, D Morales-Espinosa, A Ruelas-Villavicencio, ... BMC cancer 7 (1), 1-9, 2007 | 172 | 2007 |
| Influence of taste disorders on dietary behaviors in cancer patients under chemotherapy K Sánchez-Lara, R Sosa-Sánchez, D Green-Renner, C Rodríguez, ... Nutrition Journal 9, 1-6, 2010 | 165 | 2010 |
| Lung cancer in never smokers: The role of different risk factors other than tobacco smoking L Corrales, R Rosell, AF Cardona, C Martin, ZL Zatarain-Barron, O Arrieta Critical reviews in oncology/hematology 148, 102895, 2020 | 158 | 2020 |
Luis CorralesCIMCA / HSJD-CCSS Costa RicaVerified email at cimcacr.com
